Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.
Feuerstein graduated from Emory University with a bachelor's degree in political science.
Recent Articles By The Author
Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer
The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.
XBiotech Silent as Deadline for European Resubmission of Colon Cancer Drug Passes
The XBiotech drug, Xilonix, had no effect on the size of colon cancer tumors with zero complete or partial responses reported in the phase III study.
Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO
Ludwig Hantson takes over the top Alexion job after serving as CEO of Baxalta, which he helped sell to Shire for $32 billion.
Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study
Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.